NVAF
VTE
CAD
PAD
ACS
TKR
THR
General
Anticoagulation management for patients with NVAF, CKD and other comorbidities
Antenna Study
The Antenna study provides real world evidence suggesting that patients with NVAF treated with Xarelto® have a reduced risk of adverse renal outcomes compared to warfarin.
The mean annual decline in eGFR was lower in patients receiving Xarelto than those receiving warfarin.
Comorbidities in the real world: non-valvular atrial fibrillation and chronic kidney disease
In this video Dr Rob Lewis, Consultant Nephrologist, Wessex Kidney Centre, talks about the impact of chronic kidney disease on the heart with particular reference to non-valvular atrial fibrillation and anticoagulation management, reflecting that nowadays patients often present with comorbidities.
Not all patients are the same. What matters the most to you?
Footnotes
NVAF, non-valvular atrial fibrillation; eGFR, estimated glomerular filtration rate.
RP-XAR-GB-5141 | February 2024
- expand_more